Neurology & Neurocritical Care
3Guideline Neurology / Neuropharmacology Practice-changing Grade: Moderate
This joint AAN/AHS guideline reorganizes migraine preventive selection around evidence confidence, tolerability, safety, and cost while integrating CGRP-targeted agents into first-line options for both episodic and chronic migraine.
Guideline Hemorrhagic Stroke Practice-changing Grade: High
The guideline introduces significant updates in blood pressure management and anticoagulation reversal strategies for ICH.
🔓 Free Teaser Guideline Traumatic Brain Injury Practice-changing Grade: Moderate
The BTF 4th Edition revises hyperosmolar, seizure, steroid, ICP-threshold, and sedation guidance most relevant to neuro-ICU pharmacists.
Cardiology & Anticoagulation
12Guideline Cardiology / Anticoagulation
Dramatic shift to precision lipidology in ASCVD prevention.
Consensus Statement Cardiology / Anticoagulation Practice-changing Grade: Low
This European Journal of Heart Failure expert consensus reframes coronary revascularization as secondary to optimized guideline-directed medical therapy in heart failure with coronary artery disease, with direct implications for anticoagulant, antiplatelet, and anti-ischemic medication management.
Consensus Statement Cardiology / Anticoagulation Confirmatory Grade: Low
This AHA scientific statement synthesizes observational and emerging randomized evidence on caffeine and coffee across cardiovascular risk factors and diseases, giving pharmacists a framework for counseling on moderate consumption.
Guideline Pediatric Pharmacy Practice-changing Grade: Low
This inaugural Australian pediatric hypertension guideline, adapted from the AAP 2017 framework, gives pharmacists a unified national reference for BP thresholds, screening timing, and antihypertensive selection in patients under 18 years of age.
Consensus Statement Guideline: Dyslipidemia Practice-changing Grade: Low
This consensus statement recalibrates diagnostic thresholds, treatment initiation age, and LDL-C goals for children with familial hypercholesterolaemia, expanding the pharmacist's role in early lipid-lowering therapy.
Consensus Statement Cardiology / Anticoagulation Inconclusive Grade: Low
This joint ESC/EACTS clinical consensus statement addresses antithrombotic management after coronary artery bypass grafting to reduce graft occlusion and thrombotic complications.
🔓 Free Teaser Guideline Dyslipidemia Practice-changing Grade: Moderate
The 2026 ACC/AHA/Multisociety guideline introduces lower treatment goals, formal risk equations, and mandates Lp(a) assessment for dyslipidemia pharmacists.
🔓 Free Teaser Guideline Hypertension Practice-changing Grade: Moderate
The 2025 AHA/ACC Guideline introduces PREVENT-based CVD risk, new secondary hypertension triggers, and major changes in initial drug therapy for pharmacists managing hypertension.
Guideline Acute Coronary Syndrome Practice-changing Grade: Moderate
Reflects pivotal updates in antiplatelet strategy and secondary prevention for Acute Coronary Syndrome management.
🔓 Free Teaser Guideline AFib/Antithrombotics Practice-changing Grade: Moderate
Major changes in stroke risk assessment, anticoagulant preferences, and DOAC over warfarin guidance will alter daily pharmacist management of AFib patients.
🔓 Free Teaser Guideline Heart Failure Practice-changing Grade: Moderate
The 2022 AHA/ACC/HFSA guideline redefines heart failure subtypes and updates foundational recommendations for GDMT, SGLT2 inhibitors, and phenotype-directed care.
Guideline VTE/Anticoagulation Practice-changing Grade: High
CHEST provides comprehensive updates emphasizing DOAC use for VTE management without cancer.
Nephrology
2Guideline Nephrology / Renal Pharmacy Confirmatory Grade: Moderate
This narrative review maps where the four major hypertension guidelines converge and diverge for CKD patients, clarifying practical implications for BP targets, RAS inhibition, diuretic selection, and cardio-renal add-on therapies.
Guideline Chronic Kidney Disease Practice-changing Grade: Moderate
The 2024 KDIGO guideline for CKD introduces new recommendations for screening, diagnosis, risk stratification, pharmacologic intervention, and bone-mineral disorder, with significant implications for pharmacist monitoring roles.
Endocrinology & Metabolism
6Guideline Pediatric Pharmacy Practice-changing Grade: Low
This Spanish Society of Pediatric Endocrinology consensus operationalizes device-specific and situation-specific T1D management for children across emergency, sick-day, surgical, and radiation contexts.
Guideline Endocrinology / Obesity Practice-changing Grade: Moderate
The ADA's new Obesity Association standards formalize race- and ethnicity-specific BMI thresholds plus waist-based confirmatory measures, reframing obesity diagnosis around adiposity rather than BMI alone.
Guideline Gastroenterology / Hepatology Practice-changing Grade: Moderate
This November 2025 AASLD update operationalizes semaglutide (Wegovy) for F2-F3 MASH, replacing biopsy-driven selection with noninvasive test thresholds and detailing a comprehensive GLP-1 safety-monitoring framework relevant to every dispensing and clinical pharmacist.
Guideline Obesity / Weight Management Practice-changing Grade: Moderate
The ADA's new Obesity Association guideline reframes obesity pharmacotherapy around treating obesity-related diseases rather than weight targets alone, elevates GLP-1RA and dual GIP/GLP-1RA agents to preferred status across multiple comorbidities, and mandates indefinite continuation to prevent weight recurrence.
🔓 Free Teaser Guideline Diabetes Practice-changing Grade: Moderate
Introduces expanded diabetes screening and diagnostic recommendations across diverse populations for pharmacy practice.
Guideline Gastroenterology / Hepatology Practice-changing Grade: Moderate
The first joint hepatology, diabetology, and obesity guideline under the new MASLD nomenclature elevates incretin therapies and introduces resmetirom as the first approved MASH-targeted pharmacotherapy.
Pulmonary / Respiratory
5Consensus Statement Oncology / Supportive Care Confirmatory Grade: Low
This international consensus addresses how to integrate asparaginase with the now-standard frontline blinatumomab backbone, including dosing, therapeutic drug monitoring, and adaptations for resource-limited settings.
Consensus Statement Pulmonology / Respiratory Confirmatory Grade: Low
An Italian Delphi and RAND/UCLA consensus pushes pharmacists toward proactive, phenotype-informed, ICS-containing regimens rather than symptom-driven reliever use in mild-to-moderate asthma.
Guideline COPD Practice-changing Grade: Moderate
GOLD 2026 adds mepolizumab as a second eosinophil-guided biologic option and refines exacerbation-focused escalation, expanding the pharmacist's role in phenotype-driven COPD care.
🔓 Free Teaser Guideline COPD Practice-changing Grade: Moderate
The GOLD 2026 update brings significant changes impacting risk stratification, exacerbation management, biologics, and vaccination in COPD care.
Guideline Asthma Practice-changing Grade: Moderate
GINA 2021 formalizes ICS-formoterol as the preferred reliever across all adult/adolescent steps and adds new pediatric and Step 5 options.
Infectious Disease & Immunization
11Guideline Infectious Disease / Antimicrobials Practice-changing Grade: Low
The first formal AASLD/IDSA HBV guideline (versus prior guidance) tightens antiviral treatment thresholds, adds tenofovir alafenamide for pregnancy, and newly addresses horizontal transmission and expanded liver cancer surveillance.
Consensus Statement Infectious Disease / Antimicrobials Practice-changing Grade: Moderate
A new IDSA-led multisociety consensus prioritizes pharmacist-driven levers including beta-lactam-first sequencing, prolonged-infusion defaults, and second-dose timeliness to improve sepsis outcomes beyond bundle compliance.
Consensus Statement Infectious Disease / Antimicrobials
Prolonged beta-lactam infusions improve survival in severe illness.
Guideline Infectious Disease / Antimicrobials
Genetic testing can prevent irreversible hearing loss from antibiotics.
Consensus Statement Infectious Disease / Antimicrobials Practice-changing Grade: Low
Seven international societies now formally back concentration-guided beta-lactam dosing, positioning pharmacists to lead TDM and model-informed personalized dosing programs.
Guideline Women's Health Confirmatory Grade: Moderate
This targeted guideline update clarifies when to favor hormonal therapy and spironolactone over prolonged antibiotics in female acne patients, with pregnancy-specific and contraceptive counseling implications for pharmacists.
Guideline Infectious Disease / Antimicrobials Practice-changing Grade: Moderate
The 10th European Conference on Infections in Leukaemia repositions carbapenem-sparing monotherapy, risk-stratified empirical selection, and neutrophil-count-independent antibiotic discontinuation as the standard for haematology and transplant patients.
🔓 Free Teaser Guideline Immunization Practice-changing Grade: Moderate
The 2025 ACIP adult schedule features universal and risk-based expansions for pneumococcal, RSV, and polio vaccines, plus product, schedule, and note updates directly relevant to pharmacists.
🔓 Free Teaser Guideline Clostridioides difficile Infection Practice-changing Grade: High
This guideline prioritizes fidaxomicin over vancomycin and updates on adjunct therapies.
🔓 Free Teaser Guideline Community-Acquired Pneumonia Practice-changing Grade: Moderate
The 2019 ATS/IDSA CAP guideline introduces major shifts in diagnostic and empiric therapy strategies for adult patients.
Guideline Hospital-Acquired & Ventilator-Associated Pneumonia Practice-changing Grade: Low
The 2016 ATS/IDSA update reshapes empiric antibiotic selection, de-escalation, and duration of therapy for hospital-acquired and ventilator-associated pneumonia around local resistance data and pharmacokinetic optimization.
Critical Care & Sepsis
1Guideline Critical Care / ICU Practice-changing Grade: Moderate
The SCCM/ESICM 2026 update adds prehospital and MDR-stratified antimicrobial guidance, elevates prolonged beta-lactam infusion to a strong recommendation, and expands biomarker, hemodynamic, and long-term recovery statements directly relevant to ICU pharmacists.
Geriatrics
2Guideline Geriatrics / Geriatric Pharmacy
Psychotropic polypharmacy poses significant risks in Alzheimer's disease.
🔓 Free Teaser Guideline Beers Criteria Practice-changing Grade: Moderate
The 2023 AGS Beers Criteria update introduces significant modifications and new recommendations impacting antihyperglycemics, anticoagulants, anticholinergics, and select drug–disease interactions for older adults.
Pharmacogenomics
1Guideline Pharmacogenomics Practice-changing Grade: Moderate
The strength of recommendation to avoid clopidogrel in CYP2C19 intermediate metabolizers is elevated to strong, and genotype-guided antiplatelet therapy now formally extends to neurovascular indications.
Therapeutic Drug Monitoring
2Guideline Pharmacokinetics / TDM Practice-changing Grade: Low
The AGNP TDM task force delivers a systematically revised, evidence-based set of therapeutic and dose-related reference ranges for 160 neuropsychiatric drugs, plus integrated pharmacogenetic guidance, giving TDM pharmacists new interpretive tools and expanded drug coverage.
Guideline Vancomycin TDM Practice-changing Grade: High
The latest vancomycin guidelines prioritize AUC-guided monitoring over traditional trough levels for MRSA infections.
Other
2Guideline Rheumatology / Immunology Practice-changing Grade: Low
The American College of Rheumatology reframes non-renal SLE management around universal hydroxychloroquine, aggressive glucocorticoid tapering, and earlier immunosuppressive escalation.
🔓 Free Teaser Guideline Rheumatology / Immunology Confirmatory Grade: Moderate
The 2025 EULAR rheumatoid arthritis recommendations abandon prognostic-factor stratification after methotrexate failure and endorse less frequent laboratory monitoring after early tolerance, both directly relevant to ambulatory pharmacists managing DMARD regimens and adherence.
More Coming Soon
Guidelines and consensus statements currently in the analysis pipeline: